How Investors Are Reacting To Henry Schein (HSIC) Earnings Miss On Softer U.S. Dental Product Demand

• Earlier this week, Henry Schein reported that although its Q2 2025 revenue surpassed expectations, adjusted earnings per share missed forecasts due to reduced demand for U.S. dental products amid high interest rates and inflation.
• This performance comes as the company continues its investor outreach at major healthcare conferences and highlights sustained commitment to corporate citizenship initiatives through programs supporting students globally.
• We'll now explore how the recent earnings shortfall and softer dental demand may influence Henry Schein's future investment outlook.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

Henry Schein Investment Narrative Recap

To be a Henry Schein shareholder, you need to believe the company can build on its role as a key distributor and technology provider to dental and medical practices while maintaining margins in a competitive market. The recent earnings miss and softer U.S. dental product demand highlight that the strength of dental volumes remains the main short-term catalyst, while persistent competition and cost headwinds present the biggest risk to near-term earnings. For now, the earnings news underscores these challenges but does not appear to materially change the key risk or catalyst for the business.

The company's upcoming presentations at major healthcare investor conferences are particularly relevant, as they give management an opportunity to address investor concerns following the earnings shortfall and reinforce their view on the outlook for margin recovery and growth initiatives. These forums can be important touchpoints for resetting expectations in light of recent pressures on dental product demand and margin performance.

However, investors should also be aware that in contrast to margin pressures in dental distribution, competitive pricing, especially for key consumables like gloves, continues to weigh on Henry Schein’s gross profit and remains a risk if not offset by growth in higher-margin segments…

Read the full narrative on Henry Schein (it's free!)

Henry Schein's narrative projects $14.4 billion in revenue and $614.4 million in earnings by 2028. This requires 4.0% yearly revenue growth and a $225.4 million earnings increase from $389.0 million today.

Uncover how Henry Schein's forecasts yield a $72.23 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members provided two fair value estimates for Henry Schein, spanning a wide range from US$72 to US$179. With pressure on dental product demand still present, these differing views highlight the importance of considering multiple scenarios for future profitability and margins.

Explore 2 other fair value estimates on Henry Schein - why the stock might be worth over 2x more than the current price!

Build Your Own Henry Schein Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Henry Schein research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Henry Schein research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Henry Schein's overall financial health at a glance.

Searching For A Fresh Perspective?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com